Vitamin D Deficiency and Effects of Vitamin D Supplementation on Disease Severity in Patients with Atopic Dermatitis: A Systematic Review and Meta-Analysis in Adults and Children
Sonal R Hattangdi-Haridas 1, Susan A Lanham-New 1, Wilfred Hing Sang Wong 2, Marco Hok Nutrients 2019, 11(8), 1854; https://doi.org/10.3390/nu11081854 (registering DOI)
Items in both categories Skin and Inflamation are listed here:
- Atopic Dermatitis not helped by small weekly doses of Vitamin D (8K 2y-6y.16K 12y-18y) – RCT March 2024
- Eczema (Atopic Dermatitis) treated by 1,600 IU Vitamin D (again) – Meta-analysis Aug 2019
- Increased risk of atopic dermatitis with low vitamin D during pregnancy perhaps due to poor methylation – Oct 2018
- Atopic dermatitis treated by Vitamin D (in dogs too) - RCT Feb 2018
- Eczema (Atopic Dermatitis) treated by 1600 IU of vitamin D – meta-analysis Dec 2016
- Atopic Eczema might be helped by Vitamin D – Review May 2015
- Dermatologists still not convienced that Vitamin D reduces atopic dermatitis – Review Dec 2013
- Eczema 25 percent more likely if low vitamin D– July 2013
- Atopic dermatitis dramatically reduced in Iran with 1600 IU of vitamin D – RCT March 2012
- Atopic Dermatitis and Eczema - many studies
- Atopic dermatitis worse for those with low vitamin D – Nov 2010
Download the PDF from VitaminDWiki
Kung Ho 2 and Andrea L Darling 1,*
- 1 Department of Nutritional Sciences, School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, GU2 7XH, UK
- 2 Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Research has investigated 25-hydroxyvitamin D (25(OH)D) levels in the Atopic Dermatitis (AD) population, as well as changes in AD severity after vitamin D (VitD) supplementation. We performed an up-to-date systematic review and meta-analysis of these findings. Electronic searches of MEDLINE, EMBASE and COCHRANE up to February 2018 were performed. Observational studies comparing 25(OH)D between AD patients and controls, as well as trials documenting baseline serum 25(OH)D levels and clinical severity by either SCORAD/EASI scores, were included. Of the 1085 articles retrieved, sixteen were included. A meta-analysis of eleven studies of AD patients vs. healthy controls (HC) found a mean difference of −14 nmol/L (95% CI −25 to −2) for all studies and −16 nmol/L (95% CI −31 to −1) for the paediatric studies alone. A meta-analysis of three VitD supplementation trials found lower SCORAD by −11 points (95% CI −13 to −9, p < 0.00001). This surpasses the Minimal Clinical Important Difference for AD of 9.0 points (by 22%). There were greater improvements in trials lasting three months and the mean weighted dose of all trials was 1500–1600 IU/daily. Overall, the AD population, especially the paediatric subset, may be at high-risk for lower serum 25(OH)D. Supplementation with around 1600 IU/daily results in a clinically meaningful AD severity reduction.